Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hanmi Science Co (008930) Fair Value & Analysis

Healthcare · KR · Market cap 2.0T KRW

Price27,350 KRW
Fair Value29,718 KRW
Upside+8.7%
Quality95/100
Evidence: High Range 13,933 KRW – 38,515 KRW

Analysis

Hanmi Science Co (008930) currently trades at 27,350 KRW, while our model-based Fair Value estimate is 29,718 KRW — implying the stock looks roughly 8.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

McKesson Corporation (M1CK34) +22% Cencora, Inc (C1CO34) -44% Cardinal Health, Inc (CAH) -49% Sigma Healthcare Limited (SIGGF) -67% Sitka Gold Corp (SIG) -59% Shanghai Pharmaceuticals Holding (601607) +112%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.